ASCO 2024 | ABBV-400 with fluorouracil, folinic acid and bevacizumab in previously treated mCRC

Kanwal Pratap Singh Raghav, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase II randomized study evaluating the safety and efficacy of ABBV-400 in combination with 5-FU, folinic acid (FA), and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) after first-line treatment. The study aims to optimize the dose of ABBV-400 and assess its efficacy using objective response and progression-free survival as primary endpoints. Enrollment began in November 2023, with ongoing dose escalation and dose optimization stages. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.